Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities
Share: Geneva, Switzerland, December 14, 2020 – Addex Therapeutics Ltd (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for a proposed underwritten public offering of shares, including those to be settled in the form of American Depositary Shares (ADSs). Each ADS represents the right to receive six shares ...
Source: benzinga.com